

## Exploring the Novel Trends in Orphan Drugs and Rare Diseases

**Jason Haxton**

Museum of Osteopathic Medicine and the International Center for Osteopathic History, U.S.A, E-mail: [jhaxton@atsu.edu](mailto:jhaxton@atsu.edu)

Orphan Drugs 2020 is an International Rare Diseases Conference, encompassing genetically caused rare diseases and fundamental research and development in respective field. It is a Global platform reaching across all the rare diseases around the globe, covers research and developments of new treatments. The conference attains significance when we look at the worldwide deaths due to Rare Diseases, about 30% of children with [rare diseases](#) will die before reaching their fifth birthday.

Orphan Drugs Conference was focused on such tracks like Development Trends and Strategies on Orphan Drugs, Challenges in Rare Diseases, [Orphan Drugs](#) Pricing and Reimbursement, Genetic Rare Diseases, Clinical Research on Rare Diseases, Ethical Issues on Rare Diseases, Drug Approvals for Rare Diseases, Entrepreneurs Investment Meet. So we invite researchers, specialists, professionals, experts and research fellows, professors, association and societies, and every one share their knowledge by giving the oral, poster and e-poster presentations in this unique platform. where you will be sure to have a meaningful experience with scholars from around the world. All members of the Orphan Drugs 2020 organizing committee look forward to meeting you in Prague, Czech Republic.

The worldwide [pharmaceutical](#) medications market was esteemed at around \$962.1 billion in 2012, which is the parent advertise for orphan drugs. FDA and European Commission are included in giving unique kind of convention to organizations that are encountering business hindrances, for example, item rivalry and inventory network barriers. The aggregate number of infections arranged as orphan stands at around 7,000 at present, with almost 250 new maladies being annexed to this rundown every year

Orphan drug sales expanded by \$85 billion from the earlier year. That contrasts and a 2.1% decrease in general physician endorsed medicate deals, which tumbled to \$645 billion. Kyprolis, a medication from Onyx Pharmaceuticals for numerous myeloma, was the most encouraging new vagrant medication in 2012, with U.S. deals anticipated that would reach \$897 million in 2020. With the overall orphan

drug market set to reach \$127 billion by 2018, representing about 16% of aggregate physician recommended sedate deals, it's turning into the following field for some of pharma's greatest leaps forward and fiercest patent wars. FDA market research analyst has estimated the global orphan drugs market to exhibit a moderate growth rate during the forecast period and is envisaged to surpass USD 156 billion by 2020.

**Contact:**

Jessica Roy | Program Manager  
Pharmaceutical Sciences 2020  
[orphandrugs@europemeet.org](mailto:orphandrugs@europemeet.org)